Vital Signs - Specialty Generics - Next Wave of Generics Growth


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on April 2, 2007, provides a strategic overview of the potential for specialty generics in the pharmaceutical industry. Additionally, an emerging company profile is provided for Abrika Pharmaceuticals, an emerging specialty generic pharmaceuticals company. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of March 19 - March 23, 2007.

Table of Contents

Vital Signs - Specialty Generics - Next Wave of Generics GrowthVital Signs: 2 April 2007This week's issue:




Related Research

Release Date : 09-Jan-18

Region : North America

Release Date : 03-Jan-18

Region : North America

Release Date : 29-Dec-17

Region : North America

Release Date : 28-Dec-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.